These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 41560

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of the new beta-adrenoceptor blocking agent betaxolol (SL 75212) in man after repeated oral administration.
    Bianchetti G, Blatrix C, Gomeni R, Kilborn JR, Larribaud J, Lücker PW, Thebault JJ, Trocherie S, Morselli PL.
    Arzneimittelforschung; 1980; 30(11):1912-6. PubMed ID: 6109538
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [The pharmacokinetics of 1-(4-cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane (talinolol, Cordanum, 02-115) 2. Excretion, blood level and distribution of the 14C-labeled compound in the rat].
    Klemm W, Wenzel A.
    Pharmazie; 1975 Oct; 30(10):675-7. PubMed ID: 695
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of butofilolol (CAFIDE) after repeated oral administration in man.
    Houin G, Barre J, Jeanniot JP, Ledudal P, Cautreels W, Tillement JP.
    Int J Clin Pharmacol Res; 1984 Oct; 4(3):175-83. PubMed ID: 6149195
    [Abstract] [Full Text] [Related]

  • 7. Effects of a meal and its composition on the bioavailability of betaxolol administered orally to healthy subjects.
    Thiercelin JF, Bianchetti G, Larribaud J, Ganansia J, Deves C, Trocherie S, Abriol C, Morselli PL.
    World Rev Nutr Diet; 1984 Oct; 43():183-6. PubMed ID: 6147938
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Blood concentrations and pharmacodynamic effects of SL 75212, a new beta-adrenoceptor antagonist, after oral and intravenous administration [proceedings].
    Bianchetti G, Gomeni R, Kilborn JR, Morselli PL, Taylor EA, Warrington SJ.
    Br J Clin Pharmacol; 1979 Oct; 8(4):403P-404P. PubMed ID: 41556
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Metabolic studies in patients with nadolol: oral and intravenous administration.
    Dreyfuss J, Brannick LJ, Vukovich RA, Shaw JM, Willard DA.
    J Clin Pharmacol; 1977 Oct; 17(5-6):300-7. PubMed ID: 16040
    [Abstract] [Full Text] [Related]

  • 20. Tissue distribution of exaprolol in rat.
    Faberová V, Trnovec T, Zemánek M, Bezek S, Durisová M, Tomcíková O.
    Eur J Drug Metab Pharmacokinet; 1985 Oct; 10(1):11-3. PubMed ID: 2863149
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.